The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Baudax Bio’s investigational regulatory T-cell therapy TI-168…
Articles by Andrea Lobo, PhD
The U.S. Food and Drug Administration (FDA) has cleared for laboratory use CRYOcheck Factor VIII Deficient Plasma with…
The National Hemophilia Foundation (NHF) has changed its name to the National Bleeding Disorders Foundation (NBDF) to reflect its…
Dosing has begun in a Phase 2b clinical trial evaluating the safety and efficacy of SerpinPC, Centessa Pharmaceuticals’…
Switching to a different clotting factor VIII (FVIII) product was not linked to a greater risk of developing neutralizing antibodies…
Incidences of bleeding from playing sports are rare among people with hemophilia, and more likely to occur in those…
Despite preventive treatment, people with hemophilia A or B report lower quality of life, mainly due to poor joint…
MRI screening can identify subclinical joint bleeding in some patients with severe hemophilia A on preventive treatment, according to…
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Hemlibra’s (emicizumab) approval be expanded…